编号：2018-003 证券代码：000881 证券简称：中广核技 中广核核技术发展股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|------------------------------|------------------------------------------------------| | | | | | 投资者关系活动类别 | √ 特定对象调研 □分析师会议 | | | | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | 来访人员 | 广州金域投资有限公司 | | | | | 投资管理部 研究经理 魏宏伟 | | 时间 | 2018 年 11 月 21 | 日下午 4:00 | | 地点 | 中广核大厦北楼 16 | 层 1631 会议室 | | 上市公司接待人员 | | 董事会工作部负责人兼证券事务代表 吴卫卫 | | 活动主要内容 | 一、公司基本情况介绍 | | | 介绍 | 二、问答环节 | | | | | 1、电子加速器当前订单交付情况 ...

编号：2021-004 证券代码：000881 证券简称：中广核技 中广核核技术发展股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|---------------------------------|--------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 □ | 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 □ | 其他 | | 参与单位名称及 人员姓名 | 太平洋证券股份有限公司 | 机械研究员 曾博文 | | 时间 | 2021 年 6 月 21 | 日 | | 地点 | 电话会议 | | | 上市公司接待人 员姓名 | 董事会秘书 董事会工作部总经理 | 杨新春、 唐海军、证券事务代表 吴卫卫 | | ...

编号：2021-006 证券代码：000881 证券简称：中广核技 中广核核技术发展股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|---------------------------------|------------------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | □ 其他 | | 参与单位名称及 | 招商证券环保首席分析师 | 朱纯阳、国信证券化工首席分析师黄 | | 人员姓名 | | 道立、前海九九资本管理公司合伙人 高琳、越秀证券公司研究 | | | 经理 | 麦启宇、厚特投资公司投资总监 陆飞、 NTF Asset 新同方资 | | | 管财务总监兼风控 明等机构来宾共 | 杨涛、南方睿泰基金管理公司客服经理 赖旭 30 人及机构客户 | | | | | | ...

证券代码：000881 证券简称：中广核技 编号：2021-008 中广核核技术发展股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | 分析师会议 | | 类别 | □ 媒体采访 | 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 □ | 其他 | | 参与单位名称及 人员姓名 | 国联证券科技行业研究员 | 华庆 | | 时间 | 2021 年 11 月 30 | 日 | | 地点 | 电话会议 | | | 上市公司接待人 员姓名 | 董事会秘书 | 杨新春、证券事务代表 吴卫卫 | | 记录 | 1. 公司子公司逾 | 70 家，组织架构相对复杂，业务呈多样性，体 | | | 现在 " 焦在某一方面？ | 更美丽，更安全，更健康 " 三个方面，未来是否会着重聚 | | ...

证券代码：000881 证券简称：中广核技 编号：2022-001 中广核核技术发展股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-------------------------|------------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | 分析师会议 | | 类别 | □ 媒体采访 | 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | □ 其他 | | 参与单位名称及 | | 上海申银万国证券研究所有限公司 机械行业分析师 刘建伟 | | 人员姓名 | 国海证券股份有限公司 | 权益投资部 高级分析师 韩诚 | | 时间 | 2022 年 1 月 17 | 日 | | 地点 | 电话会议 | | | 上市公司接待人 员姓名 | 董事会秘书 | 杨新春、证券事务代表 吴卫卫 | | 记录 | 1. 面并行？ | 公司业务类型较多，未来是否会着重聚焦在某一方面还是多方 | | ...

编号：2022-002 证券代码：000881 证券简称：中广核技 中广核核技术发展股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | 分析师会议 | | 类别 | 媒体采访 | 业绩说明会 | | | 新闻发布会 | 路演活动 | | | 现场参观 | 其他 | | 参与单位名称及 人员姓名 | 国联证券科技行业研究员 | 华庆 | | 时间 | 2022 年 2 月 24 日 | | | | | | | 地点 | 电话会议 | | | 上市公司接待人 员姓名 | 副总经理 | 王西坡、董事会秘书 杨新春、证券事务代表 吴卫卫 | | 记录 | 1. | ...

Financial Performance - The company reported a revenue of RMB 1.5 billion for the first half of 2022, representing a year-on-year increase of 15%[13] - The net profit attributable to shareholders was RMB 300 million, up 20% compared to the same period last year[13] - The company's operating revenue for the reporting period was ¥4,314,818,290.49, representing a 29.42% increase compared to ¥3,334,090,601.80 in the same period last year[19] - The net profit attributable to shareholders decreased by 4.31% to ¥123,828,800.99 from ¥129,404,203.52 year-on-year[19] - The net profit after deducting non-recurring gains and losses was -¥2,138,197.81, a decline of 104.34% compared to ¥49,257,291.71 in the previous year[19] - The net cash flow from operating activities improved significantly to ¥102,939,944.83, a 148.92% increase from -¥210,432,547.22 in the same period last year[19] - Total assets at the end of the reporting period were ¥12,915,353,370.15, down 3.05% from ¥13,322,236,426.35 at the end of the previous year[19] - The company's net assets attributable to shareholders increased by 1.96% to ¥6,221,427,564.11 from ¥6,102,062,628.27 year-on-year[19] - The company reported a weighted average return on equity of 2.00%, a decrease of 0.15 percentage points from 2.15% in the previous year[19] Investment and R&D - The company plans to invest RMB 500 million in R&D for new technologies and products in the upcoming year[13] - The company is exploring potential mergers and acquisitions to enhance its technological capabilities and market presence[13] - The company is actively optimizing its major asset restructuring in sectors such as ocean transportation and real estate development[25] - The company has filed 25 new patent applications and received 73 new patent authorizations in the first half of the year, demonstrating its commitment to innovation[49] - The company is committed to the development of nuclear technology applications, which are increasingly recognized at the national level[36] - The company is enhancing its technological innovation capabilities, aiming to improve system integration and result transformation as part of its "442" innovation framework[112] Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 30% increase in market share by 2025[13] - User data indicates a growth of 25% in active users of the company's services, reaching 2 million users by June 2022[13] - The company is focusing on expanding its market presence in the fields of medical materials and packaging materials[28] - The company is actively pursuing market opportunities in the proton tumor treatment equipment and special waste treatment sectors, despite facing challenges due to its relatively short development time in these areas[113] Sales and Revenue Growth - The company signed 34 new accelerator orders in the first half of the year, with electronic accelerator sales increasing by 25% year-on-year and sales of disinfection and sterilization accelerators rising by 83.33%[54] - The new product sales in the radiation cross-linked materials segment exceeded CNY 180 million, while sales of optical communication products increased by 20% year-on-year, reaching 66,000 tons[57] - The import and export trade segment saw a significant revenue increase of 748.11%, totaling ¥1,038,069,591.17, up from ¥122,398,289.25 in the same period last year[61] - Revenue from ocean transportation grew by 50.37% to ¥395,210,824.54, driven by a 15% increase in the BSI index and higher business volume[61][64] - Domestic revenue accounted for 89.92% of total revenue, amounting to ¥3,880,032,226.03, with a year-on-year growth of 27.65%[61] Risk Management - The company has identified key risk factors, including regulatory changes and market competition, and has developed strategies to mitigate these risks[13] - The company is implementing measures to mitigate risks associated with accounts receivable and inventory, including tracking customer credit status and linking sales incentives to cash collection[111] - The company has established a monthly tracking mechanism for risk management indicators to ensure proactive responses to various operational risks[107] Environmental and Safety Management - The company has established an environmental management system to enhance its environmental control capabilities and compliance with regulations[128] - The company maintained a safety production record with zero serious injuries over 1,972 days, ensuring stable operations during critical periods[131] - The company plans to enhance safety culture, standardization, and environmental management in the second half of the year, aiming for stable safety performance[131] Shareholder and Governance - No cash dividends or stock bonuses will be distributed to shareholders for this period[4] - The company held four shareholder meetings during the reporting period, with participation rates of 41.27%, 40.30%, 45.30%, and 50.35% respectively[117] - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital for the semi-annual period[122] - The company has not implemented any stock incentive plans, employee stock ownership plans, or other employee incentive measures during the reporting period[123] Subsidiaries and Related Transactions - The company reported significant net profit contributions from its subsidiaries, with 中广核高新核材料集团有限公司 achieving a net profit of CNY 39,724,621.67, representing over 10% of the company's overall net profit[101] - 中广核俊尔新材料有限公司 generated a revenue of CNY 828,090,442.49 and a net profit of CNY 14,495,713.22 during the reporting period[101] - The company disposed of several subsidiaries, generating a total disposal gain of CNY 563.51 thousand from the sales of 大连国合出国人员培训学校, 大连豪华轿车租赁有限公司, and others[105] Legal and Compliance - As of June 30, 2022, the company had 12 pending lawsuits as the plaintiff, involving approximately 26.0099 million yuan, and 2 lawsuits as the defendant, involving approximately 27.8699 million yuan[140] - The company reported no significant non-operating fund occupation by controlling shareholders or related parties during the reporting period[135] - The company had no violations regarding external guarantees during the reporting period[136]

Financial Performance - The company's operating revenue for Q1 2022 was ¥1,964,657,949.31, representing a 37.20% increase compared to ¥1,431,968,178.28 in the same period last year[3]. - Net profit attributable to shareholders was ¥38,099,280.83, a 62.86% increase from ¥23,393,983.09 year-on-year[3]. - Basic earnings per share increased by 63.16% to ¥0.0403 from ¥0.0247 in the same period last year[3]. - Net profit for Q1 2022 reached CNY 66,936,584.05, representing a 47.9% increase from CNY 45,271,249.38 in Q1 2021[24]. - The company reported a comprehensive income total of CNY 62,832,936.35 for Q1 2022, compared to CNY 43,594,400.83 in Q1 2021[25]. Cash Flow - The net cash flow from operating activities improved to -¥61,231,440.33, a 43.59% reduction in losses compared to -¥108,547,615.51 in the previous year[3]. - Total cash inflow from operating activities was 2,232,869,505.59, compared to 1,785,863,652.82 in the previous period, reflecting a 25% increase[27]. - Cash outflow from operating activities totaled 2,294,100,945.92, up from 1,894,411,268.33, representing a 21% increase[29]. - Cash flow from investment activities showed a net outflow of -43,182,602.56, an improvement from -582,081,887.70 in the previous period[29]. - The ending balance of cash and cash equivalents was 1,571,366,566.46, down from 1,859,306,586.37, reflecting a decrease of approximately 15%[30]. Assets and Liabilities - Total assets at the end of the reporting period were ¥13,092,686,712.12, a decrease of 1.72% from ¥13,322,236,426.35 at the end of the previous year[3]. - The total liabilities as of Q1 2022 amounted to CNY 6,358,396,790.57, down from CNY 6,647,331,935.01 at the end of the previous year[20]. - The company’s total liabilities included short-term borrowings of RMB 2,345,048,585.36, an increase from RMB 2,236,700,597.37[18]. - The company’s fixed assets decreased to RMB 2,709,611,414.59 from RMB 2,744,883,932.58, reflecting a reduction in fixed asset value[18]. Sales and Revenue - Cash received from sales of goods and services was ¥1,991,772,375.14, a 36.08% increase from ¥1,463,689,600.79 in the previous year[8]. - Total operating revenue for Q1 2022 was CNY 1,964,657,949.31, an increase of 37.1% compared to CNY 1,431,968,178.28 in the same period last year[23]. - Total operating costs for Q1 2022 were CNY 1,966,865,334.06, up 35.7% from CNY 1,449,517,796.31 year-over-year[23]. Investments and Contracts - The company signed contracts for the sale of six vessels with a total transaction value of USD 9,665,000, with all deposits received as of the announcement date[14]. - The company plans to participate in a nuclear technology application industry development fund initiated by the government of Mianyang, focusing on civil nuclear technology applications[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 41,474[9]. - The total equity attributable to shareholders of the parent company was CNY 6,137,570,726.35, an increase from CNY 6,102,062,628.27 year-over-year[20].

Financial Performance - The company's operating revenue for 2021 was ¥7,998,857,682.91, representing a 20.25% increase from ¥6,651,679,590.05 in 2020[32]. - The net profit attributable to shareholders for 2021 was ¥176,723,237.79, a decrease of 34.82% compared to ¥271,123,164.82 in 2020[32]. - The net profit after deducting non-recurring gains and losses was ¥53,309,874.16, down 70.34% from ¥179,764,504.15 in the previous year[32]. - The net cash flow from operating activities was ¥475,720,066.83, a decline of 13.09% from ¥547,361,013.97 in 2020[32]. - The total assets at the end of 2021 were ¥13,322,236,426.35, an increase of 8.14% from ¥12,319,715,091.57 at the end of 2020[32]. - The net assets attributable to shareholders at the end of 2021 were ¥6,102,062,628.27, up 2.21% from ¥5,969,876,957.74 in 2020[32]. - The company reported a basic earnings per share of ¥0.1869 for 2021, down 34.83% from ¥0.2868 in 2020[32]. - The weighted average return on equity for 2021 was 2.93%, a decrease of 1.69 percentage points from 4.62% in 2020[32]. - The company received government subsidies amounting to ¥142,156,783.61 in 2021, compared to ¥61,375,741.50 in 2020[34]. Business Expansion and Strategy - The company has expanded its main business to include electronic accelerator manufacturing, irradiation processing services, new materials, ecological environment, and medical health since the major asset restructuring completed in early 2017[25]. - The company aims to create a safer living environment and provide healthier life services through its nuclear technology initiatives[3][4][5]. - The company is actively expanding its business layout, including projects in special waste treatment and medical health, to create new competitive advantages[96]. - The company is enhancing its electronic accelerator technology to improve waste treatment capabilities and expand into new application areas[59]. - The company is focusing on the medical health sector, particularly in proton therapy equipment and medical isotopes, while also addressing market expansion challenges in these areas[152]. - The company is expanding its irradiation processing business, particularly in material modification, to meet the growing demand driven by new infrastructure projects in China[55]. Market Trends and Opportunities - The global irradiation processing industry is growing at an annual rate of approximately 10%, with China's industrial electron irradiation accelerators averaging over 10% growth in the past five years, and an expected growth rate of 10% to 15% from 2021 to 2025[36]. - The domestic medical sterilization service market currently holds a 12% industry share, indicating significant future growth potential[37]. - The market for electron beam treatment of special waste is expanding rapidly, particularly in industrial wastewater treatment, with notable achievements in sectors such as textile dyeing and medical waste[37]. - The domestic market for radioactive isotopes is heavily reliant on imports, with only 20% of the demand for 131I being met by domestic production, highlighting a significant opportunity for local production growth[41]. - The modified plastics industry has achieved significant advancements over the past decade, becoming a vital part of China's economy and narrowing the gap with developed countries[39]. Research and Development - The company holds 284 authorized patents, including 76 invention patents, demonstrating its strong R&D capabilities[80]. - Research and development expenses increased by 6.81% to ¥238,295,491.44 compared to the previous year[118]. - The number of R&D personnel rose by 18.05% to 556, with the proportion of R&D personnel in the company increasing to 12.16%[122]. - Total R&D investment amounted to ¥318,615,066.97, reflecting a 20.79% increase year-on-year[122]. - The company has established partnerships with three leading universities to foster innovation in nuclear technology[169]. Corporate Governance and Management - The company is committed to maintaining a "strict, cautious, detailed, and practical" work attitude in response to new challenges and tasks in the current environment[65]. - The company has established a robust internal control system and governance structure, ensuring compliance with legal and regulatory requirements[158]. - The company has established an independent asset structure with complete control over its production system and procurement processes[159]. - The company maintains a fully independent financial management system, with no instances of fund occupation by the controlling shareholder[163]. - The company emphasizes investor relations management to protect the rights of minority shareholders[159]. Future Outlook - The company expects a revenue growth of 10% for the upcoming fiscal year, projecting a total revenue of 11 billion RMB[172]. - The company plans to enhance ship safety management and increase operational efficiency in 2022, aiming for higher rental income through various pricing strategies[76]. - The company aims to strengthen accelerator research and manufacturing, focusing on applications in waste treatment, new materials, and health services[145]. - The 2022 operational plan emphasizes high-quality development and the implementation of the A+ strategy, positioning the year as a "year of implementation"[146]. - The company is exploring opportunities for mergers and acquisitions to strengthen its market position and expand its service offerings[185].

中广核核技术发展股份有限公司 2019 年半年度报告全文 中广核核技术发展股份有限公司 2019 年半年度报告 2019 年 08 月 1 中广核核技术发展股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人林坚、主管会计工作负责人秦庚及会计机构负责人（会计主管 人员）王晓阳声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司请投资者认真阅读半年度报告，报告中涉及未来计划、发展战略等前 | --- | |-------------------------------------------------------------------------------------------| | | | | | 瞻性陈述不构成公司对投资者的实质承诺。投资者及相关人士均应当对此保持 | | 足够的风险认识，并且应当理解计划、预测与承诺之间的差异。 | | 公司已在本报告中详细描述公司可能 ...